| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1774 | |
| Phytochemical name or plant extracts | Schizophyllan | |
| PMID | 22552717 | |
| Literature evidence | This coupled with the ability of SCH to suppress hepatic lesions associated with TAM treatment provides the rationale for further investigating the combined therapeutic effects of TAM+SCH in preclinical models of ER-positive breast cancer, as well as in liver cancer. | |
| IUPAC name | 4-[3,5-dihydroxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol | |
| Phytochemicals’ class or type of plant extracts | Polysaccharide | |
| Source of phytochemicals or plant Extracts | Schizophyllum commune | |
| Geographical availability | NA | |
| Plant parts | Mushroom | |
| Other cancers | Breast cancer, Liver cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | TAM was more effective than SCH in the induction of apoptosis in both mammary and hepatic carcinomas. | |
| Cell line/ mice model | Female adult swiss albino mice | |
| Additional information | This coupled with the ability of SCH to suppress hepatic lesions associated with TAM treatment provides the rationale for further investigating the combined therapeutic effects of TAM+SCH in preclinical models of ER-positive breast cancer, as well as in liver cancer. | |
| PubChem ID | 21868524 | |
| Additional PMIDs | NA | |
| Additional sources of information | NA | |
| Safety | NA |